Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Gardiner, S. J. Articles by Rampono, J. Search for Related Content PubMed Citation Articles by Gardiner, S. J. Articles by Rampono, J. Child/Adolescent Psychiatry Gender Atypical Neuroleptics

Transfer of Olanzapine Into Breast Milk, Calculation of Infant Drug Dose, and Effect on Breast-Fed Infants

OBJECTIVE: This study characterized infant drug doses and breast-milk-to-plasma area-under-the-curve ratios for olanzapine and determined plasma concentrations and effects of this drug on breast-feeding infants. METHOD: Seven mother-infant nursing pairs were studied. Olanzapine was measured in plasma and milk with high-performance liquid chromatography over a dose interval (for six patients) or at a single time after dose ingestion (for one patient) at steady state. Infant drug exposure was estimated as the product of an assumed milk production rate and average drug concentration in milk, normalized to body weight, and expressed as a percentage of maternal drug dose, normalized to body weight. RESULTS: The median infant dose of olanzapine ingested through milk was 1.02% of the maternal dose; the median milk-to-plasma area-under-the-curve ratio was 0.38 for the six patients with data collected over the dose interval. Corresponding values in the patient with single-point data were 1.13% and 0.75. Olanzapine was not detected in the plasma of the six infants with an evaluable plasma sample. All of the infants were healthy and experienced no side effects. CONCLUSIONS: Breast-fed infants were exposed to a calculated olanzapine dose of approximately 1%—well below the 10% notional level of concern. In infant plasma, olanzapine was below the detection limit; there were no adverse effects on the infants. These data support the use of olanzapine during breast-feeding. However, the authors recommend that breast-fed infants be monitored closely and the decision to breast-feed be made after individual risk-benefit analysis.

This article has been cited by other articles:

				D. Yaeger, H. G. Smith, and L. L. Altshuler Atypical Antipsychotics in the Treatment of Schizophrenia During Pregnancy and the Postpartum Am J Psychiatry, December 1, 2006; 163(12): 2064 - 2070. [Full Text] [PDF]

				D. Kohen Psychotropic medication and breast-feeding Advan. Psychiatr. Treat., September 1, 2005; 11(5): 371 - 379. [Abstract] [Full Text] [PDF]

				W. Aichhorn, C. Stuppaeck, and A. B. Whitworth Risperidone and breast-feeding J Psychopharmacol, March 1, 2005; 19(2): 211 - 213. [Abstract] [PDF]

				L. Howard, R. Webb, and K. Abel Safety of antipsychotic drugs for pregnant and breastfeeding women with non-affective psychosis BMJ, October 23, 2004; 329(7472): 933 - 934. [Full Text] [PDF]

				M. V. Seeman Gender Differences in the Prescribing of Antipsychotic Drugs Am J Psychiatry, August 1, 2004; 161(8): 1324 - 1333. [Abstract] [Full Text] [PDF]

				S. Gentile Clinical Utilization of Atypical Antipsychotics in Pregnancy and Lactation Ann. Pharmacother., July 1, 2004; 38(7): 1265 - 1271. [Abstract] [Full Text] [PDF]

				Recent References J Hum Lact, February 1, 2004; 20(1): 106 - 112. [PDF]

				Olanzapine Use During Maternity: How Does It Affect Infants? Journal Watch Psychiatry, October 8, 2003; 2003(1008): 6 - 6. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2003 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us